search
Back to results

Safety and Efficacy of the SETA LATECBA Stent Graft for EVAR in Subjects With AAA

Primary Purpose

Abdominal Aortic Aneurysm

Status
Unknown status
Phase
Not Applicable
Locations
Canada
Study Type
Interventional
Intervention
SETA LATECBA Stent Grafts
Sponsored by
Latecba S.A.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Abdominal Aortic Aneurysm

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Male and female adults older than 18 years old, willing to cooperate with the study. No other demographic restriction.
  • Initial diagnosis of AAA according to the standard of care criteria following the guidance Clinical Practice Guidelines for Endovascular Abdominal Aortic Aneurysm Repair
  • Medical history: Complete history of previous, present and concomitant conditions, and current treatments for other conditions Signed informed consent. If the patient cannot consent, the subject's legally acceptable representative should consent

Diagnosis of Abdominal Aortic Aneurysm (AAA) according to the following criteria:

  1. Diagnosis of an abdominal aortic aneurysm with a diameter ≥ 5.0 cm for males or ≥ 4.5 cm for females.
  2. Aneurysm diameter with a growth rate ≥ 0.5 cm/ 6 months
  3. The juxtarenal neck length between 1 mm and 10 mm
  4. Neck diameter ≥16 to ≤ 26 mm
  5. Suprarenal aorta diameter ≥ infrarenal aorta diameter
  6. Proximal neck angulated ≤ 60 degrees relative to the long axis of the aneurysm
  7. Immediate suprarenal aorta angulated ≤ 60 degrees relative to the immediate infrarenal neck.
  8. Common iliac diameter 8 to 20 mm.
  9. Common iliac length 25 mm
  10. Common iliac angle 60 degrees
  11. Not eligible for other standard EVAR surgical procedure

Exclusion Criteria:

  • General Exclusion Criteria

    1. Life expectancy less than 2 years
    2. Pregnant or breastfeeding or planning on becoming pregnant within 60 months
    3. Included in another investigative drug or device study/studies or planning to do it within the following 24 months

Medical Exclusion Criteria

  1. Previous treatment of AAA
  2. Known allergy to polyester, stainless steel, nitinol and or gold, teflon, nylon,
  3. Known anaphylactic reaction to contrast media.
  4. Any type coagulopathy untreated.
  5. Genetic connective tissue diseases, such as Marfan or Ehlers-Danlos syndromes
  6. Planned interventional or surgical procedure within 30 days before or after AAA repair.
  7. Renal dysfunction: creatinine level over 1.7 mg/dl
  8. Systemic infection or fever over 38°C

    AAA Anatomy Exclusion Criteria

  9. Significant occlusive disease, tortuosity, or calcification.

i) Significant thrombus in the fixation sites. j) Fungal aneurysm k) Leaking/ruptured or symptomatic aneurysm. l) Traumatic aneurysm. m) Concurrent aneurysm of the thoracic aorta. n) One or both renal arteries coming from the aneurysmal sac. o) Proximal neck diameter, measured outer wall to outer wall on a sectional image (CTA) > 26 mm in diameter or < 16 mm in diameter p) Proximal neck angle > 60 degrees relative to the long axis of the aneurysm q) Immediate suprarenal aorta angle > 60 degrees relative to the immediate infrarenal neck.

r) Immediate suprarenal aorta angle > 60 degrees relative to the immediate infrarenal neck s) Aortic diameter, measured inner wall to inner wall on a sectional image (CTA) < 15 mm at the bifurcation t) Iliac/femoral anatomy that is unsuitable for access. u) Iliac artery diameter, measured outer wall to outer Wall on a sectional image (CTA) > 20 mm or < 8 mm at distal fixation site.

v) Iliac artery distal fixation site < 10 mm in length. w) Indispensable inferior mesenteric artery (IMA)

Sites / Locations

  • Centre Hospitalier Universitaire SherbrookeRecruiting

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

treatment arm

Arm Description

SETA LATECBA Stent Grafts, are tube shaped implantable devices, delivered by balloon catheter system which are intended to the treatment of infrarenal AAA by sealing the affected areas, avoiding the bleeding or perfusion inside the aneurysm and restoring the normal hemodynamics in the affected vessels. The product family is composed by a set of endovascular stent grafts, that can be used alone or in combination, according to the treatment strategy, extension and complexity of the AAA. One aortic bifurcated stent graft, ABK SETA LATECBA model, is the aortic trunk and two straight iliac stent grafts, RIK SETA LATECBA model, are the connections to both iliac arteries.

Outcomes

Primary Outcome Measures

EFFICACY: Number of participants with Endoleak Type I (measured by Angio CT Scan)
Type I endoleaks is diagnosed when there is a gap between the stent graft and the vessel wall. Usually is a result of the failure of the stent graft to achieve a circumferential seal of the aneurism. It produces systemic pressurization of the aneurysm sac and increases the risk of sac rupture.
SAFETY: mortality
percentage of died subjects

Secondary Outcome Measures

SAFETY: Major Adverse Events
Composite endpoint including Q-wave myocardial infarction, Congestive heart failure, Cardiac ischemia requiring intervention Renal failure requiring dialysis, Bowel obstruction, ischemia or fistula, Stroke, Paralysis, Aneurysm leak and Device related death
Incidence of post-operative complications
Complications of aneurysm repair followed by secondary interventions
Clinical success
Composite endpoint including Successful deployment at intended site, No migration, Aneurysm exclusion, no type III and/or IV endoleak, No graft infection, No graft thrombosis, No aneurysm rupture, No conversion to open repair,
Clinical success
Composite endpoint including No migration, Aneurysm exclusion, no type I, III and/or IV endoleak, No graft thrombosis, No aneurysm rupture. No aneurysm diameter expansion >5 mm, No conversion to open repair
Clinical success
Composite endpoint including No migration, Aneurysm exclusion, no type I, III and/or IV endoleak, No graft thrombosis, No aneurysm rupture. No aneurysm diameter expansion >5 mm, No conversion to open repair
Technical Success of stent-graft implantation and delivery system usage
Composite endpoint including Assessment of system performance (Procedural times, Total blood loss, Deployment and device patency Ease of insertion, Visualization, Delivery system retrieval, Device integrity, Kinks, No type IV endoleak) Ancillary equipment needed, Adjunctive maneuvers (Balloon dilatation of aortic neck Balloon dilatation of iliac arteries, Additional stent or surgical procedure required, Eventual use of proximal cuff, Contrast media volume)

Full Information

First Posted
January 5, 2020
Last Updated
January 6, 2020
Sponsor
Latecba S.A.
search

1. Study Identification

Unique Protocol Identification Number
NCT04220177
Brief Title
Safety and Efficacy of the SETA LATECBA Stent Graft for EVAR in Subjects With AAA
Official Title
Prospective, Open-label, Multicenter, Non-randomized Clinical Study to Determine the Safety and Efficacy of SETA LATECBA Stent Graft for Endovascular Repair Therapy (EVAR) in Subjects With Abdominal Aortic Aneurysm (AAA).
Study Type
Interventional

2. Study Status

Record Verification Date
January 2020
Overall Recruitment Status
Unknown status
Study Start Date
December 11, 2019 (Actual)
Primary Completion Date
December 31, 2021 (Anticipated)
Study Completion Date
March 31, 2022 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Latecba S.A.

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
This is a Prospective, Open-label, Multicenter, and Non-randomized Clinical Study. The main purpose of this study is to establish the efficacy and safety of a medical device system, SETA LATECBA Stent Graft, intended for the treatment of EVAR of pararenal AAA (patients with complex anatomy, not eligible for other surgical procedure).Other objective is to evaluate the technical performance of the device SETA LATECBA Stent Graft.
Detailed Description
This is a Prospective, Open-label, Multicenter, and Non-randomized Clinical Study to determine the Safety and Efficacy of the SETA LATECBA Stent Graft for endovascular repair therapy (EVAR) in Subjects with Abdominal Aortic Aneurysm (AAA)..The main purpose of this study is to establish the efficacy and safety of a medical device system, SETA LATECBA Stent Graft, intended for the treatment of Endovascular Aneurysm Repair (EVAR) of pararenal AAA (patients with complex anatomy, not eligible for other surgical procedure). Secondary objective(s): The secondary objective is to evaluate the technical performance of the device SETA. LATECBA Stent Graft which includes: access to the implantation site, visualization, deployment of the stent- graft, sizing compatibility, withdrawal of the delivery system, and compatibility with ancillary equipment.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Abdominal Aortic Aneurysm

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Model Description
Prospective, Open-label, Multicenter, Non-randomized
Masking
None (Open Label)
Allocation
N/A
Enrollment
42 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
treatment arm
Arm Type
Experimental
Arm Description
SETA LATECBA Stent Grafts, are tube shaped implantable devices, delivered by balloon catheter system which are intended to the treatment of infrarenal AAA by sealing the affected areas, avoiding the bleeding or perfusion inside the aneurysm and restoring the normal hemodynamics in the affected vessels. The product family is composed by a set of endovascular stent grafts, that can be used alone or in combination, according to the treatment strategy, extension and complexity of the AAA. One aortic bifurcated stent graft, ABK SETA LATECBA model, is the aortic trunk and two straight iliac stent grafts, RIK SETA LATECBA model, are the connections to both iliac arteries.
Intervention Type
Device
Intervention Name(s)
SETA LATECBA Stent Grafts
Other Intervention Name(s)
ABK SETA LATECBA, RIK SETA LATECBA
Intervention Description
ABK model is a bifurcated polyester graft partially corrugated which is sutured at the proximal end (renal) to a balloon expandable 316 L stainless steel stent. The proximal half part of the stent is uncovered by polyester graft providing the anchoring to the healthy aorta wall when the device is implanted, as well as the perfusion of the renal arteries. The remaining half part is covered by polyester graft providing sealing of the aneurysm when it is expanded upon on the graft fabric and aneurysm neck. The distal end of each branch has the anchorage site for sealing after the connection with the iliac extensions RIK. The diameter of the anchorage site varies with the different ABK codes. The end of one branch is cone-shaped after the anchoring diameter with the purpose of promoting insertion of iliac extension RIK. The connection to iliac arteries is achieved by completing the aortic trunk ABK with 2 iliac extensions RIK.
Primary Outcome Measure Information:
Title
EFFICACY: Number of participants with Endoleak Type I (measured by Angio CT Scan)
Description
Type I endoleaks is diagnosed when there is a gap between the stent graft and the vessel wall. Usually is a result of the failure of the stent graft to achieve a circumferential seal of the aneurism. It produces systemic pressurization of the aneurysm sac and increases the risk of sac rupture.
Time Frame
30 days
Title
SAFETY: mortality
Description
percentage of died subjects
Time Frame
30-day
Secondary Outcome Measure Information:
Title
SAFETY: Major Adverse Events
Description
Composite endpoint including Q-wave myocardial infarction, Congestive heart failure, Cardiac ischemia requiring intervention Renal failure requiring dialysis, Bowel obstruction, ischemia or fistula, Stroke, Paralysis, Aneurysm leak and Device related death
Time Frame
30-day
Title
Incidence of post-operative complications
Description
Complications of aneurysm repair followed by secondary interventions
Time Frame
12 months
Title
Clinical success
Description
Composite endpoint including Successful deployment at intended site, No migration, Aneurysm exclusion, no type III and/or IV endoleak, No graft infection, No graft thrombosis, No aneurysm rupture, No conversion to open repair,
Time Frame
30-day
Title
Clinical success
Description
Composite endpoint including No migration, Aneurysm exclusion, no type I, III and/or IV endoleak, No graft thrombosis, No aneurysm rupture. No aneurysm diameter expansion >5 mm, No conversion to open repair
Time Frame
6 months
Title
Clinical success
Description
Composite endpoint including No migration, Aneurysm exclusion, no type I, III and/or IV endoleak, No graft thrombosis, No aneurysm rupture. No aneurysm diameter expansion >5 mm, No conversion to open repair
Time Frame
12 months
Title
Technical Success of stent-graft implantation and delivery system usage
Description
Composite endpoint including Assessment of system performance (Procedural times, Total blood loss, Deployment and device patency Ease of insertion, Visualization, Delivery system retrieval, Device integrity, Kinks, No type IV endoleak) Ancillary equipment needed, Adjunctive maneuvers (Balloon dilatation of aortic neck Balloon dilatation of iliac arteries, Additional stent or surgical procedure required, Eventual use of proximal cuff, Contrast media volume)
Time Frame
12 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Male and female adults older than 18 years old, willing to cooperate with the study. No other demographic restriction. Initial diagnosis of AAA according to the standard of care criteria following the guidance Clinical Practice Guidelines for Endovascular Abdominal Aortic Aneurysm Repair Medical history: Complete history of previous, present and concomitant conditions, and current treatments for other conditions Signed informed consent. If the patient cannot consent, the subject's legally acceptable representative should consent Diagnosis of Abdominal Aortic Aneurysm (AAA) according to the following criteria: Diagnosis of an abdominal aortic aneurysm with a diameter ≥ 5.0 cm for males or ≥ 4.5 cm for females. Aneurysm diameter with a growth rate ≥ 0.5 cm/ 6 months The juxtarenal neck length between 1 mm and 10 mm Neck diameter ≥16 to ≤ 26 mm Suprarenal aorta diameter ≥ infrarenal aorta diameter Proximal neck angulated ≤ 60 degrees relative to the long axis of the aneurysm Immediate suprarenal aorta angulated ≤ 60 degrees relative to the immediate infrarenal neck. Common iliac diameter 8 to 20 mm. Common iliac length 25 mm Common iliac angle 60 degrees Not eligible for other standard EVAR surgical procedure Exclusion Criteria: General Exclusion Criteria Life expectancy less than 2 years Pregnant or breastfeeding or planning on becoming pregnant within 60 months Included in another investigative drug or device study/studies or planning to do it within the following 24 months Medical Exclusion Criteria Previous treatment of AAA Known allergy to polyester, stainless steel, nitinol and or gold, teflon, nylon, Known anaphylactic reaction to contrast media. Any type coagulopathy untreated. Genetic connective tissue diseases, such as Marfan or Ehlers-Danlos syndromes Planned interventional or surgical procedure within 30 days before or after AAA repair. Renal dysfunction: creatinine level over 1.7 mg/dl Systemic infection or fever over 38°C AAA Anatomy Exclusion Criteria Significant occlusive disease, tortuosity, or calcification. i) Significant thrombus in the fixation sites. j) Fungal aneurysm k) Leaking/ruptured or symptomatic aneurysm. l) Traumatic aneurysm. m) Concurrent aneurysm of the thoracic aorta. n) One or both renal arteries coming from the aneurysmal sac. o) Proximal neck diameter, measured outer wall to outer wall on a sectional image (CTA) > 26 mm in diameter or < 16 mm in diameter p) Proximal neck angle > 60 degrees relative to the long axis of the aneurysm q) Immediate suprarenal aorta angle > 60 degrees relative to the immediate infrarenal neck. r) Immediate suprarenal aorta angle > 60 degrees relative to the immediate infrarenal neck s) Aortic diameter, measured inner wall to inner wall on a sectional image (CTA) < 15 mm at the bifurcation t) Iliac/femoral anatomy that is unsuitable for access. u) Iliac artery diameter, measured outer wall to outer Wall on a sectional image (CTA) > 20 mm or < 8 mm at distal fixation site. v) Iliac artery distal fixation site < 10 mm in length. w) Indispensable inferior mesenteric artery (IMA)
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Ezequiel Klimovsky, MD
Phone
54 11 4952 1360
Email
eklimovsky@quid-consulting.com
First Name & Middle Initial & Last Name or Official Title & Degree
Francisco Barone, Eng
Phone
54 11 49120064
Email
fbarone@latecba.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
The-Bao Bui, MD
Organizational Affiliation
Centre Hospitalier Universitaire Sherbrooke
Official's Role
Principal Investigator
Facility Information:
Facility Name
Centre Hospitalier Universitaire Sherbrooke
City
Sherbrooke
State/Province
Montreal
Country
Canada
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Guylaine Provencher, MD
Phone
819 8206480

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Safety and Efficacy of the SETA LATECBA Stent Graft for EVAR in Subjects With AAA

We'll reach out to this number within 24 hrs